| Generic name | Fedratinib |
| Brand name(s), other common name(s) | Inrebic® |
| Drug type | Kinase inhibitor |
| How the drug is given | Oral |
Indications and Usage
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Side effects needing medical attention
Diarrhea, nausea, anemia, and vomiting.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.